Dr. Tricia Cottrell
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.
Dr. Tricia Cottrell is a clinician scientist whose research focuses on tumour-immune interactions in solid tumours, and the identification of predictive and prognostic biomarkers in pre-treatment and post-treatment tumour tissues. Cottrell completed her MD, PhD, Anatomic Pathology Residency, and postdoctoral training at Johns Hopkins University School of Medicine and is now an Assistant Professor in the Department of Pathology and Molecular Medicine at Queen’s University.
Some of Dr. Cottrell’s research contributions include the first characterization of the features of immune-mediated tumour regression following neoadjuvant anti-PD-1 therapy in non-small cell lung carcinoma. This first published clinical trial was used to develop a set of proposed immune-related pathologic response criteria for the standardized and reproducible assessment of pathologic response following neoadjuvant immunotherapy. These criteria are now being evaluated in a large clinical trial of neoadjuvant anti-PD-1 therapy in non-small cell lung carcinoma. These findings have also been extended to other tumor types and efforts to develop a pan-cancer method for quantifying pathologic response are underway.
Dr. Cottrell is Senior Investigator in the Canadian Cancer Trials Group (CCTG) in Kingston and the Deputy Director of CCTG’s Tumour Tissue and Data Repository.
See Dr. Cottrell’s recent publications on PubMed or on Google Scholar.
To collaborate with Dr. Cottrell, please contact her directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.
